4.6 Review

Broadening horizons: the role of ferroptosis in cancer

Journal

NATURE REVIEWS CLINICAL ONCOLOGY
Volume 18, Issue 5, Pages 280-296

Publisher

NATURE RESEARCH
DOI: 10.1038/s41571-020-00462-0

Keywords

-

Categories

Funding

  1. Agence National de la Recherche (ANR)-Projets blancs
  2. ANR
  3. Association pour la recherche sur le cancer
  4. Canceropole Ile-de-France
  5. Chancelerie des universites de Paris (Legs Poix)
  6. Fondation Carrefour
  7. Fondation pour la Recherche Medicale
  8. Gustave Roussy Odyssea
  9. European Union Horizon 2020 Project Oncobiome
  10. High-end Foreign Expert Program in China [GDW20171100085, GDW20181100051]
  11. Inserm (HTE)
  12. Institut National du Cancer
  13. Institut Universitaire de France
  14. LabEx Immuno-Oncology
  15. LeDucq Foundation
  16. Ligue contre le Cancer (equipe labellisee)
  17. RHU Torino Lumiere
  18. Seerave Foundation
  19. SIRIC Stratified Oncology Cell DNA Repair and Tumour Immune Elimination (SOCRATE)
  20. SIRIC Cancer Research and Personalized Medicine (CARPEM)
  21. European Research Area Network on Cardiovascular Diseases (ERA-CVD, MINOTAUR)

Ask authors/readers for more resources

Ferroptosis is an iron-dependent form of regulated cell death driven by excessive lipid peroxidation, and can be induced by various agents to suppress tumor growth while also potentially triggering inflammation-associated immunosuppression. The extent of ferroptosis's impact on tumor biology and its interactions with other signaling pathways are still under investigation.
Ferroptosis is an iron-dependent form of regulated cell death driven by excessive lipid peroxidation. Pharmacological agents, ionizing radiation and cytokines can induce ferroptosis and thus suppress tumour growth, but ferroptosis can also trigger inflammation-associated immunosuppression. The authors describe the key molecular mechanisms of ferroptosis, including crosstalk with tumour-associated signalling pathways, and discuss potential therapeutic applications of ferroptosis. The discovery of regulated cell death processes has enabled advances in cancer treatment. In the past decade, ferroptosis, an iron-dependent form of regulated cell death driven by excessive lipid peroxidation, has been implicated in the development and therapeutic responses of various types of tumours. Experimental reagents (such as erastin and RSL3), approved drugs (for example, sorafenib, sulfasalazine, statins and artemisinin), ionizing radiation and cytokines (such as IFN gamma and TGF beta 1) can induce ferroptosis and suppress tumour growth. However, ferroptotic damage can trigger inflammation-associated immunosuppression in the tumour microenvironment, thus favouring tumour growth. The extent to which ferroptosis affects tumour biology is unclear, although several studies have found important correlations between mutations in cancer-relevant genes (for example, RAS and TP53), in genes encoding proteins involved in stress response pathways (such as NFE2L2 signalling, autophagy and hypoxia) and the epithelial-to-mesenchymal transition, and responses to treatments that activate ferroptosis. Herein, we present the key molecular mechanisms of ferroptosis, describe the crosstalk between ferroptosis and tumour-associated signalling pathways, and discuss the potential applications of ferroptosis in the context of systemic therapy, radiotherapy and immunotherapy.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available